FDA Approves Lymphir: A New Hope for CTCL Patients
The U.S. Food and Drug Administration (FDA) had approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Updated on: August 12,2024
0
FDA Approves Lymphir: A New Hope for CTCL Patients
The U.S. Food and Drug Administration (FDA) had approved Lymphir (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
Updated on:August 12,2024
0